Leah Amir

X

Leah Amir

Leah Amir

Clinical & Technical Advisory

 

Over 20 years of success commercializing new products delivering clinical solutions leading to improved patient outcomes in the areas of diagnostics and therapeutic in cardiovascular disease, orthopedics, gynecology, oncology, neurology and tissue regeneration.  She has developed a stellar team of seasoned experts.

Clients include Mallinckrodt Medical, Boston Scientific, Zimmer, Lab Corp, Molecular Diagnostics, Medtronic, Biosphere Medical, Radiotherapeutics, Omnisonics, Laserscope,  Osteotech,  Veran  Medical  Technologies,  Merit Medical,  OrthoSensor,  Mobius  Therapeutics,  Sharecare  Healthways, MolecuLight  and others.  She leads a team of highly qualified specialists in science, regulatory, clinical trials management, and healthcare finance.  She has published extensively on health economics of medical interventions, trained sales teams on consultative selling and presented to numerous hospital value added committees.

Leveraging IT expertise from VantageLinks, LLC a WBE and the research arm -The Institute for Quality Resource Management (IQRM)- our customers gain turn key solutions aiding product development, testing by medical professionals, software development, statistical analysis all brought together to meet the expectation of the FDA and payers.

Armed with a Master of Science and Master of Healthcare Administration from Washington University School of Medicine coupled with over 20 years of success she is delivering knowledge of science, quality control, manufacturing for USP and FDA products aiding her clients regulatory process. As the manager of quality control at Mallinckrodt Medical she had clearance from the FBI and DEA to conduct microbial testing of all in process and finished narcotics and products containing controlled substances. In addition, she was responsible for the microbial and contaminate testing of the manufacturing environment and the water used in various manufacturing environments.  She did pyrogen testing for medical products sold to Germany complying with the strictest manufacturing specifications.

Post graduate education received at Wharton Leonard Davis Institute cost effectiveness/outcomes analysis, and Harvard Patient Safety from the Institute for Healthcare Improvement with honors support her skills to create and use methods to collect information, validate improved clinical outcomes, economic metrics, and relate this information in support of regulatory success including coding and payment. She is an active participant in the Healthcare Financial Management Association (HFMA), American College of Healthcare  Executives  (ACHE),  Wound  Healing  Society  (WHS),  American  Heart  Association (AHA) a member of the Advisory Board for Boston Med Tech Transfer, on the editorial board of Today’s Wound Clinic, and a mentor at the Center for Emerging Technologies in St. Louis, MO.  

Paul Magnin

X

Paul Magnin

Clinical & Technical Advisory

 

Paul Magnin spent 17 years as a key contributor to Hewlett-Packard’s Ultrasound Imaging business. He was the R&D Manager of Hewlett-Packard’s Imaging Systems business from 1992 through 1995 and General Manager from 1996 through 1998. From 1999 through 2003, Dr. Magnin was the President and CEO of LightLab Imaging. LightLab Imaging, a medical device start-up company, brought to market a proprietary technology that employs infrared light to make images with resolution on the micron scale for Cardiology, Endoscopy, Neurology, and Surgical Microscopy. He managed the company from the start-up phase through the sale of the company to Goodman Ltd. Subsequently he was the Founder and CEO of Novelis, Inc. a privately funded start-up focused on guiding therapy for crossing Chronic Total Occlusions. Novelis was sold to Volcano Corporation in 2008.

Dr. Magnin is an advisor and board member of a number of medical device start-up companies and was the Chairman of the Board of Directors of Ultrasonix Medical Corp. in Vancouver, BC. He holds over 20 patents and has authored over 20 scientific journal articles. He has been studying and working in medical imaging since 1977 while an undergraduate at Princeton University. In 1981 he completed his doctorate in Biomedical Engineering at Duke University where he was part of the Ultrasonic Imaging research team.

Dr. Paul Magnin

X

Paul Magnin

Clinical & Technical Advisory

 

Paul Magnin spent 17 years as a key contributor to Hewlett-Packard’s Ultrasound Imaging business. He was the R&D Manager of Hewlett-Packard’s Imaging Systems business from 1992 through 1995 and General Manager from 1996 through 1998. From 1999 through 2003, Dr. Magnin was the President and CEO of LightLab Imaging. LightLab Imaging, a medical device start-up company, brought to market a proprietary technology that employs infrared light to make images with resolution on the micron scale for Cardiology, Endoscopy, Neurology, and Surgical Microscopy. He managed the company from the start-up phase through the sale of the company to Goodman Ltd. Subsequently he was the Founder and CEO of Novelis, Inc. a privately funded start-up focused on guiding therapy for crossing Chronic Total Occlusions. Novelis was sold to Volcano Corporation in 2008.

Dr. Magnin is an advisor and board member of a number of medical device start-up companies and was the Chairman of the Board of Directors of Ultrasonix Medical Corp. in Vancouver, BC. He holds over 20 patents and has authored over 20 scientific journal articles. He has been studying and working in medical imaging since 1977 while an undergraduate at Princeton University. In 1981 he completed his doctorate in Biomedical Engineering at Duke University where he was part of the Ultrasonic Imaging research team.

Stacey Kline

X

Stacey Kline

Impact Partner

Stacey is an Impact Partner with iGan Partners.

Stacey is the founder and managing director of The Good Fund – an impact fund that invests in startups solving some of the world’s biggest challenges. Prior to founding The Good Fund, Stacey was the Director of innovation projects at Goodmans LLP, driving strategic initiatives and projects aimed at addressing change in the legal market. Stacey also practiced corporate law at Goodmans.

Stacey’s interest in driving positive change extends to her volunteer involvements. Stacey serves as Chair of the Board of Save a Child’s Heart and is a member of the Advisory Board of SickKids’ Innovators Program. Stacey also serves on the board of OCAD U CO.

Stacey holds a JD from Osgoode Hall Law School, a MSc from the London School of Economics and a BA (Hons) from the University of King’s College.

Miguel Widjaja

X

Miguel Widjaja

Analyst

Joining the investment team, Miguel supports in the diligence, execution and sourcing of iGan’s investments. Prior to joining iGan Partners, Miguel worked with early stage companies at Ryerson University’s start-up incubator program: the DMZ, where he helped in areas of business development, operations and fundraising. He was also a partner at enLight, a student run non-profit where he helped organize and run multiple conferences and hackathons focused on fostering entrepreneurship in universities across Canada.

 

Miguel graduated with an Honours Bachelor’s degree in Commerce specializing in Entrepreneurial Finance, from the Queen’s School of Business. He is a recipient of the Junior Achievement: Canadian Youth Leadership Award for his social entrepreneurial work in Chameleon Pencils, a non-profit which sent school supplies to underprivileged children around the world.

Trish Barbato

X

0 (2)

Trish Barbato

Clinical & Technical Advisory

SVP, Innovation at Revera

Trish Barbato provides strategic leadership for Revera in the area of innovation, one of the company’s core strategic priorities, and oversees the Information Technology function. She has deep experience in private, public and non-profit sectors of the health system, and served as Senior Vice President of Revera Home Health from 2010 to 2015. Before joining Revera in 2010, Ms. Barbato was President and CEO of COTA Health (mental health and rehabilitation services). She was Vice President, Corporate Services and Chief Financial Officer of Providence Healthcare, and Managing Director of Bayshore Healthcare. Ms. Barbato defines success as exceeding resident expectations, keeping employees deeply engaged and being open to new ideas. She’s a Chartered Professional Accountant Fellow, holds an Economics degree from the University of Waterloo and a Queen’s Diamond Jubilee award recipient.

Sachin Aggarwal

X

b7JegjLu_400x400

Sachin Aggarwal

Clinical & Technical Advisory

CEO, Think Research

Sachin is the Chief Executive Officer of Think Research, Sachin Aggarwal understands that health care systems around the world are on the brink of profound, necessary change. Scientific knowledge, clinical best practices and medical data are increasing at an exponential rate, contributing to a global knowledge crisis – with implications for clinicians, patients, governments and countries at large.

In the midst of this growing problem, Sachin sees data as the solution – and the key to system transformation. This principle drives the mission of Think Research: to organize the world’s health knowledge so that everyone gets the best care.

As part of this vision, Sachin led Think Research in 2010 through a strategic transition to become a cloud-based service provider. The move has positioned Think Research as a leader in the global health data economy, allowing the company to standardize care at scale, aggregate knowledge across health systems and improve the quality of care for patients.

When he’s not advocating for disruptive change in health care, Sachin is actively engaged in his community. A recipient of Canada’s Top 40 Under 40 Award in 2017, Sachin also sits on the Board of the Council of Canadian Innovators. He previously served as the Deputy Chief of Staff for the Office of the Leader of the Opposition prior to joining Think Research. He’s currently a Senior Fellow in Public Policy at the Munk School of Global Affairs and Public Policy, and has served as an advisor to numerous start-up and scale-up companies in the innovation sector. He was called to the Bar in Ontario and New York, and holds an MBA from the Rotman School of Management.

Mike Stein

X

Picture3

Mike Stein

Clinical & Technical Advisory

Former CEO, CAPREIT

Mr. Stein is the founder, Chairman and CEO of the MPI Group, a property development and investment group with a track record in incubating, investing in, and managing successful companies. Between 1978 and 1987, Mr. Stein held progressively senior positions with the Mortgage Insurance Company of Canada, ultimately holding the position of Executive Vice-President responsible for operations. Mr. Stein is the founding CEO and Chairman of CAPREIT, Canada’s first TSX listed apartment REIT, where he continues to serve as Chairman. He currently serves as a director of First Service Corporation (TSX), chairman of Cliffside Capital Ltd. (TSX-V) and previously served as a director of CSA Management and Goldcorp Inc. 

Mr. Stein is a graduate engineer and has an MBA in finance and international business from Columbia University.

Dr. Andrew Padmos

X

andrew padmos

Dr. Andrew Padmos

Clinical & Technical Advisory

CEO, the royal college of physicians and surgeons in Canada

Andrew Padmos, BA, MD, FRCPC, FACP, FRCP joined the Royal College as the new CEO on September 1, 2006. He comes to the Royal College from Halifax, N.S., where from 1998 he was commissioner of Cancer Care Nova Scotia, head of the Cancer Care Program at the QEII Health Sciences Centre, associate dean for cancer programs in the Faculty of Medicine at Dalhousie University and vice-president of research, academic affairs and quality for Capital District Health Authority. Prior to working for Cancer Care Nova Scotia, Dr. Padmos was the director and CEO of the Kingston Regional Cancer Centre in Kingston, Ont., and professor and head of oncology at Queen’s University, Kingston General and Hotel Dieu hospitals.

Educated in political science and economics at the University of Toronto and in medicine at McMaster University, Dr. Padmos completed specialty training in internal medicine and hematology and was certified by the Royal College in 1976. A hematologist by profession, Dr. Padmos practised medicine in Calgary, Alta., for two years before a 15-year term at King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia. During this time, he introduced a bone marrow transplant program, developed a large clinical program in hematology/oncology and served in many administrative capacities.

Dr. Frank Prendergast

X

l

Dr. Frank Prendergast

Clinical & Technical Advisory

President, Wodlinger Consulting

Franklyn G. Prendergast, M.D., Ph.D., is a consultant in the Department of Molecular Pharmacology and Experimental Therapeutics and the Department of Biochemistry and Molecular Biology at Mayo Clinic in Rochester. He holds the academic rank of professor of biochemistry, molecular biology and pharmacology. In addition, he is recognized with the distinction of a named professorship, the Edmond and Marion Guggenheim Professorship of Biochemistry and Molecular Biology. He served as director of Mayo Clinic Cancer Center from 1994 to 2006 and currently is director of the Mayo Clinic Center for Individualized Medicine.

Dr. Prendergast obtained his medical degree with honors from the University of West Indies and attended Oxford University as a Rhodes Scholar, earning the M.A. degree in physiology. After an internal medicine residency at Mayo Clinic, Dr. Prendergast obtained the Ph.D. degree in biochemistry at the University of Minnesota/Mayo Graduate School.

Dr. Prendergast is the former chair of the Department of Biochemistry and Molecular Biology and the former director for research at Mayo Clinic in Rochester from 1989-1992. From 1989-1996, inclusive, he was a member of the Board of Governors for Mayo Clinic in Rochester. He has served on Mayo Clinic Board of Trustees continuously between 1992-2009 also has served on Mayo Clinic’s Board of Governors, the senior governance committee responsible for governance of the entire institution. He was recognized as a Mayo Distinguished Investigator in 1988.

Extramurally, Dr. Prendergast has served extensively for the National Institutes of Health (NIH) on numerous study section review groups; as a charter member of the Board of Advisors for the Division of Research Grants, now the Center for Scientific Review; the National Advisory General Medical Sciences Council; the Board of Scientific Advisors of the National Cancer Institute. He held a Presidential Commission for service on the National Cancer Advisory Board. Dr. Prendergast also has served in numerous other advisory roles for the NIH and the National Research Council of the National Academy of Sciences, and he is a member of the board of directors of the Translational Genomics Research Institute and the Infectious Disease Research Institute (IDRI).